Retatrutide Phase 3 Results: How 31% Weight Loss Compares to Other GLP-1s

The TRIUMPH-4 trial confirms retatrutide achieves up to 31% weight loss, setting a new benchmark in GLP-1 therapy.

The 31% Milestone

Retatrutide's Phase 3 results showing 31% mean weight loss represent the highest efficacy reported in any GLP-1 receptor agonist trial to date. This exceeds tirzepatide's 22.5% (SURMOUNT-1) and semaglutide's 15% (STEP-1) at comparable time points.

The magnitude of weight loss approaches bariatric surgery outcomes, which typically achieve 25-35% total body weight loss. This raises important questions about whether retatrutide could serve as a non-surgical alternative for patients who qualify for bariatric intervention.

Head-to-Head Context

While direct comparison trials are ongoing, indirect comparisons suggest retatrutide's advantage comes from its triple receptor activity (GLP-1, GIP, glucagon). The glucagon receptor activation adds an energy expenditure component that dual agonists lack, potentially explaining the superior weight loss magnitude.

📊 Dosage Calculator & Protocol Chart

Use our free Retatrutide dosage calculator to plan your protocol:

👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.

👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: retatrutide, weight loss, GLP-1, phase 3, triple agonist

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content